Related Experiment Videos
Process map proposal for the validation of genomic biomarkers.
Federico Goodsaid1, Felix Frueh
1US Food and Drug Administration, Genomics Group, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, Building 21, Room 3663, Silver Spring, MD 20903-0002, USA. Federico.Goodsaid@fda.hhs.gozv
Pharmacogenomics
|August 5, 2006
Summary
Establishing a consensus on interpreting genomic biomarker results in regulatory submissions is crucial for advancing their application in drug development. A transparent validation process benefits both pharmaceutical companies and regulatory agencies.
Area of Science:
- Genomics
- Drug Development
- Regulatory Science
Background:
- Novel genomic biomarkers hold significant potential for improving drug development.
- Standardized interpretation of these biomarkers in regulatory submissions is currently lacking.
- This hinders the widespread adoption of genomic biomarkers in pharmaceutical research.
Purpose of the Study:
- To explore strategies for encouraging the application of novel genomic biomarkers in drug development.
- To emphasize the need for consensus on interpreting genomic biomarker results for regulatory submissions.
- To highlight the value of a transparent genomic biomarker validation process.
Main Methods:
- Discussion of process map proposals for genomic biomarker validation.
- Analysis of the benefits of a transparent validation process for stakeholders.
- Consideration of how to facilitate regulatory acceptance of genomic biomarkers.
Main Results:
- A consensus on interpreting genomic biomarker data is a key enabler for their use.
- A transparent validation process offers value to both the pharmaceutical industry and regulatory bodies.
- Process map proposals can aid in developing essential guidance documents.
Conclusions:
- Developing clear guidelines for genomic biomarker validation and interpretation is essential.
- Such standardization will accelerate the integration of genomic biomarkers into drug development pipelines.
- Collaboration between industry and regulatory agencies is vital for achieving this goal.